Therefore, although the feedback mechanism involving PTEN serves to restrict the duration and impact of the PI3K pathway, in the context of tumor treatment that utilizes PI3K inhibitors, this regulatory mechanism can lead to decreased PTEN activity, ultimately reducing the effectiveness of prolonged treatment. Here, PIK3CD is linked to neoplasm.